China Resources Boya Bio pharmaceutical Group Co Ltd Financial Flexibility Index
China Resources Boya Bio pharmaceutical Group Co Ltd financial flexibility index. China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a Financial Flexibility Index of 0.14x as of December 2025. Free cash flow of CN¥159.28 Million (operating CF CN¥36.82 Million minus capex CN¥122.46 Million) represents 0% of total liabilities (CN¥1.16 Billion). See China Resources Boya Bio pharmaceutical free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of China Resources Boya Bio pharmaceutical Group Co Ltd (2009–2025)
Financial flexibility index of China Resources Boya Bio pharmaceutical Group Co Ltd from 2009 to 2025. Historical Financial Flexibility Index trend for China Resources Boya Bio pharmaceutical Group Co Ltd across 17 annual periods. Check China Resources Boya Bio pharmaceutical earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
China Resources Boya Bio pharmaceutical Group Co Ltd Financial Flexibility Index by Year (2009–2025)
China Resources Boya Bio pharmaceutical Group Co Ltd financial flexibility index by year from 2009 to 2025. Year-by-year free cash flow to debt coverage for China Resources Boya Bio pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see China Resources Boya Bio pharmaceutical operating cash flow efficiency.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.56x | CN¥651.99 Million | CN¥116.69 Million | CN¥1.16 Billion | ▲ +2.7% |
| 2024 | 0.54x | CN¥497.58 Million | CN¥299.78 Million | CN¥913.38 Million | ▼ -62.0% |
| 2023 | 1.44x | CN¥729.22 Million | CN¥641.73 Million | CN¥508.07 Million | ▲ +46.2% |
| 2022 | 0.98x | CN¥734.85 Million | CN¥596.44 Million | CN¥748.35 Million | ▼ -51.3% |
| 2021 | 2.02x | CN¥1.41 Billion | CN¥1.35 Billion | CN¥701.30 Million | ▲ +126.1% |
| 2020 | 0.89x | CN¥861.09 Million | CN¥718.58 Million | CN¥966.08 Million | ▲ +4464.1% |
| 2019 | -0.02x | CN¥-25.90 Million | CN¥-114.51 Million | CN¥1.27 Billion | ▼ -117.9% |
| 2018 | 0.11x | CN¥148.80 Million | CN¥34.90 Million | CN¥1.30 Billion | ▼ -36.7% |
| 2017 | 0.18x | CN¥213.97 Million | CN¥-23.82 Million | CN¥1.19 Billion | ▼ -89.6% |
| 2016 | 1.74x | CN¥498.84 Million | CN¥198.76 Million | CN¥287.30 Million | ▲ +58.7% |
| 2015 | 1.09x | CN¥306.39 Million | CN¥147.02 Million | CN¥280.11 Million | ▼ -39.5% |
| 2014 | 1.81x | CN¥169.78 Million | CN¥121.88 Million | CN¥93.90 Million | ▲ +133.9% |
| 2013 | 0.77x | CN¥122.00 Million | CN¥89.11 Million | CN¥157.85 Million | ▼ -82.9% |
| 2012 | 4.53x | CN¥116.81 Million | CN¥92.36 Million | CN¥25.80 Million | ▲ +210.7% |
| 2011 | 1.46x | CN¥99.79 Million | CN¥81.53 Million | CN¥68.48 Million | ▲ +132.0% |
| 2010 | 0.63x | CN¥61.42 Million | CN¥24.77 Million | CN¥97.79 Million | ▼ -11.1% |
| 2009 | 0.71x | CN¥107.28 Million | CN¥51.88 Million | CN¥151.93 Million | — |